Heterologous booster schedules are associated with increased protection against severe, omicron related COVID-19 outcomes
Explained | What is a heterologous booster vaccine, and what are its advantages? - The Hindu
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2 | Nature Communications
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study - The Lancet Respiratory Medicine
Heterologous Covid-19 Booster Vaccinations | NEJM
Study finds heterologous vaccine booster evokes robust immunity to SARS-CoV-2 Omicron variant
Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 - The Lancet Infectious Diseases
Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines: Expert Review of Vaccines: Vol 22, No 1
Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study | The BMJ
Homologous and Heterologous Covid-19 Booster Vaccinations | NEJM
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination | Nature Medicine
Sano y salvo on X: "Declaración conjunta de la @EMA_News y el @ECDC_EU sobre la posibilidad de usar dos vacunas #COVID19 diferentes, tanto para las dos primeras dosis como para la tercera
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial - The Lancet
What is a heterologous booster COVID vaccine, and why should you take this jab?, ET HealthWorld
Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health
Strategies and safety considerations of booster vaccination in COVID-19 | Biomolecules and Biomedicine
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination | NEJM
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant | Signal Transduction and Targeted Therapy
Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses | The BMJ
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination | Nature Medicine
Protective heterologous T cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigens - ScienceDirect
Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2
Covid-19 vaccine mixing: could heterologous boosters improve immunity?
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet
